P4C Boston: Wednesday, July 12, 2017

Register for P4C Boston here


State Room
60 State Street, 33rd Floor
Boston, Mass. 02109
Map and Directions

Boston 2017 session topics include:

Patient-centricity: What’s the Return on Engagement?
Patient-centricity is now widely acknowledged to be an important ingredient in R&D across the continuum, from setting research priorities through product approval. Investments of time and treasure are being made by companies, research institutions, and patient organizations alike to seek patients’ input in the process in myriad ways. Now, many stakeholders want to know, “What kind of return can I expect to get on my investment?” What quantitative and qualitative metrics can we use to assess the value of patient-centricity and patient engagement? How can patient-centricity impact the speed or outcomes of our work? How will regulators and payers take these efforts into account? Will patient-centricity gain traction beyond sound bites and goodwill?

Day 173: The Federal Policy Landscape, and Why It Matters to Boston
Beyond the mystical “100-day” mark, what significant changes are evident in Washington that will have a meaningful impact on the greater Boston medical innovation ecosystem? Get the “411” from this panel of industry and policy leaders as they dissect the latest developments regarding agency leadership and priorities, regulatory expectations, PDUFA requirements, 21st Century Cures implementation, and drug pricing debates.

Partnering for Productivity: Is Boston’s Ecosystem Populating the Pipeline?
For a number of years, the roles and relationships among academic research institutions, large and small biopharma companies, investors, and other stakeholders have been evolving in an effort to more efficiently and effectively move good ideas from labs through development to patients. The Boston area is awash with good ideas, and new models of partnership among institutions and sectors abound. What seems to be working, and why? What results are being achieved – are we seeing better rates of success, faster progress, more innovative products?

Getting What You Measure: Incentives for Collaboration
Incentives for academic and industry scientists are not always aligned with the kinds of behaviors we all say we want to see more of in science – more open sharing of data and knowledge, more team science and transdisciplinary work to solve challenging problems, more cross-sector collaboration to speed development of promising ideas. Are alternative metrics for academic advancement making any difference? Are conflict-of-interest policies helping or hurting? What levers exist to encourage culture change in life science organizations?

Reimagining the Future for Young Investigators
A record-high 80 percent of biomedical researchers with a Ph.D. are now working outside academia. Yet even after decades of national blue-ribbon commissions and reports on the need to provide more relevant training for a 21st century biomedical workforce, we’re still pushing young researchers through a system intended to turn them into academicians in the image of their forebears. Where can we look for models of students being educated for opportunities in industry, as entrepreneurs, in science at the intersection of disciplines? And for those choosing an academic path, how are we setting them up for success rather than a future of endless postdoc servitude? Who is supporting these efforts?

Workshop: Sharing “Scruffy” Data
We know that bad data produces unusable results, but gone are the days of using only pristine clinical trials data to draw conclusions and make decisions. “Scruffy” data can come in many forms: real-world data, data from wearable devices and other non-clinical trial data sets. Even if each data set is well organized and characterized, combining data sets can create disorder. In addition, there is increased interest in sharing data with non-academic partners such as citizen scientists, patient organizations and patients themselves. Is there a benefit to embracing “scruffy” data or is the goal to bring order to the data and data sharing process? What is the next frontier of dealing with the complexities of data sharing and aggregation to make sure we are obtaining meaningful results?

Workshop: Collaborating to Innovate "21st Century" Clinical Trials
Clinical trials require intense collaboration to execute, but who needs to come together to innovate the next generation of trials that are better for developers, regulators, payers, and ultimately patients? The 21st Century Cures Act provides a potential new toolkit for the community, promoting innovations such as the collection and use of patient experience data and real world evidence, enhanced qualification of medical product development tools such as biomarkers, and the use of complex adaptive and other innovative trial designs. The FDA and product developers are already working with these tools (and others such as mobile technology), but many unanswered questions remain. This workshop will bring together leaders from diverse sectors to explore how the community can collaborate to better understand the science underlying these innovations and how they can be deployed to accelerate progress.

Boston 2017 speakers include:


General Schedule


Main Room

Breakout Room

Breakout Room

8:00 AM-9:00 AM

Breakfast Roundtable Discussions



9:00 AM-9:15 AM

Intro Remarks



9:15 AM-9:30 AM

Time = Lives Talk



9:30 AM-10:30 AM

Plenary Session



10:30 AM- 11:00 AM

Networking Break

11:00 AM-12:00 PM


Panel Session


12:15 PM-12:45 PM




12:45 PM-1:45 PM

Plenary Session



1:45 PM-2:15 PM

Networking Break

2:15 PM-3:15 PM


Panel Session


3:30 PM- 4:45 PM

Plenary Session



4:45 PM- 5:00 PM

Closing Remarks



*Agenda topics and timing subject to change. FasterCures will continue to update this information as the meeting grows closer.

Sponsorship Opportunities

For information about sponsorship opportunities, please contact Lisa Simms Booth.